References
- Basic & Clinical pharmacology (6th ed.) Katzung, B. G.
- Adv. Biochem. Psychopharmacol. v.5 Some puzzling pharmacological effects of monoamine oxidase inhibitors Knoll, j.;Magyar, K.
- Eur. J. Pharmacol. v.226 The molecular pharmacology of L-deprenyl Gerlach, M.;Riederer, P.;Youdim, M. B. H.
- Nature v.265 Dopamine is a monoamine oxidase B substrate in man Glover, V.;Sandler, M.;Owen, F.;Riley, G. J.
- Acta Neurol Scand v.84 no.suppl 136 A review of the pharmacology of selegiline Heinonen, E. H.;Lammintausta, R.
- J. Pharmacol. Exp. Ther. v.189 The monoamine oxidase of brain:selective inhibition with druges and the consequences for the metabolism of the biogenic amines Yang, H. Y.;T.;Neff, N. H.
- European Journal of Pharmacology v.163 Chronic L-deprenyl-induced up-re-gulation of dopamine uptake carrier Wiener, H. L.;Hashim, A.;Lajtha, A.;Sershen, H.
- Life Sciences v.48 Deprenyl induced activities of both superoxide dismutase & catalase but not of glutathione peroxidase in the striatum of young male rat Carrillo, M. C.;Kanai, S.;Nokubo, M.;Kitani, K.
- British journal of pharmacology v.117 Protection of aged sudstantia nigra of the rat against oxidative damage by(-)-deprenyl. Cruz, C. P.;Revilla, E.;Steffen, V.;Rodriguez-Gomez, J. A.;Cano, J.;Machado, A.
- Neurosci. Lett. v.224 (-)-Deprenyl protection of 1-methyl-4-phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition Le, W.;Jankovic, J.;Xie, W.;Kong, R.;Appel, S. H.
- J. Neural. Transm., suppl v.49 Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription Tatton, W. G.;Chalmers-Redman, B. M. E.;Ju, W. Y. H.;Wadia, J.;Tatton, N. A.
- J. Neural. Transm. suppl v.41 Is selegiline neuroprotective in Parkinson's disease? Gerlach, M.;Youdim, M. B. H.;Riederer, P.
- J. Neuroch. v.63 (-)-Deprenyl reduces PC12 cell apoptosis by inducign new protein synthesis Tatton, W.G.;Ju, W. Y. L.;Holland, D. P.;Tai, C.;Kwan, M.
- J. Neural. Transm. suppl v.48 (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase Tatton, W. G.;Wadia, J. S.;AChalmer-Redman, R. M. E.;Tatton, N. A.
- Neurochem. Res. v.19 The effects of monoamine oxidase B inhibition in dopamine metabolism in rats with nigro-striatal lesions sCARR, E.;Wingerchuck, D. M.;Juorio, A. V.;Paterson, I. A.
- J. Neurochem v.65 Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats Finberg, J. P. M.;Wang, J.;Goldstein, D. S.;Kopin, I. J.;Bankiewics, K. S.
- Int. Rev. Neurol v.31 Animal models of parkinsornism using selective neurotoxins: clinical and basic implications Zigmond, M. J.;Stricker, E.
- J. Pharmcol. Exp. Ther. v.174 Effect of 6-hydroxydopamine on brain morepinephrine and dopamine: Evidence for selective degeneration of catecholamine neurons Breese, G.;Traylor, T. D.
- J. Biol. Chem. v.193 Protein measurement with the Folin phenol reagent Lowry, O. H.;Rosebrough, N. J.;Farr, A. L.;Randall, R. J.
- Br. J. Pharmacol. v.34 Evidence that dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of enzyme inhibition necessary to increase functional activity of dopamine and 5-hydroxytryptamine Green, A. R.;Mitchell, B.;Tordorff, A.
- Biochem Pharmacol. v.24 Mechanism of action of 6-hydroxyhopamine Sachs, C.;Jonsson, G.
- J. Neural. Transm. v.77 Variabillity among brain regions in the specificity of 6-hydroxydopamine (6-OHDA)-induced lesions Commins, D. L.;Shaughnessy, R. A.;Axt, K. J.;Vosmer, G.;Seiden, L. S.
- J. Neural Transm. v.22 no.SUP. The pharmacology of (-)-deprenyl Knoll, J.